
NASDAQHealthcareMedical - Diagnostics & Research
最新数据
US$164.4
+US$0.23 · +0.14%
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
收盘时
US$164.4
+US$0.23 · +0.14%
盘中时间采用ET。市场数据可能有所延迟。
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
日内区间
当前US$164.4
52周区间
当前US$164.4
盘中时间采用ET。市场数据可能有所延迟。
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
日内区间
当前US$164.4
52周区间
当前US$164.4
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 82.51亿 USD | 82.82亿 USD | 81.2亿 USD | 77.41亿 USD | 54.81亿 USD |
| 销货成本 | 60.76亿 USD | 58.45亿 USD | 57.2亿 USD | 55.27亿 USD | 39.73亿 USD |
| 毛利 | 21.76亿 USD | 24.36亿 USD | 24亿 USD | 22.14亿 USD | 15.08亿 USD |
| 销售、一般及管理费用 | 7.8亿 USD | 7.28亿 USD | 7.76亿 USD | 7.79亿 USD | 5.85亿 USD |
| 营业费用 | 11.63亿 USD | 13.39亿 USD | 14.44亿 USD | 14.19亿 USD | 11.3亿 USD |
| 利息收入 | 710.9万 USD | 860.9万 USD | 501.4万 USD | 234.5万 USD | 57.4万 USD |
| 利息支出 | 1.88亿 USD | 2.37亿 USD | 3.37亿 USD | 2.3亿 USD | 1.82亿 USD |
| 折旧和摊销 | 3.83亿 USD | 4.89亿 USD | 5.86亿 USD | 5.7亿 USD | 3.15亿 USD |
| 营业利润 | 10.12亿 USD | 10.98亿 USD | 9.56亿 USD | 7.95亿 USD | 3.79亿 USD |
| 净利润 | 2.29亿 USD | 7.91亿 USD | 6.12亿 USD | 5.05亿 USD | 1.53亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
AI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。